US Government Opposes Proposed Illumina/Grail Merger
Executive Summary
Illumina announced plans to acquire Grail for about $8bn in September 2020, but the US FTC says the proposed acquisition will diminish innovation in the US market for multi-cancer testing.
You may also be interested in...
PacBio Agrees To Pay $800M For Omniome To Add Complementary Short-Read Sequencing Platform
Pacific Biosciences has agreed to pay $600m upfront in cash and stock and up $200m in additional milestone payments to acquire Omniome. PacBio also announced a new private placement of common stock to raise $300m.
Merger Scrutiny A Bigger Risk To Pharma Than Drug Price Reform, Orzag Predicts
US antitrust regulators appear poised to take a broader view of disease areas when reviewing mergers, Lazard Freres financial advisory CEO Peter Orszag cautioned.
Merger Scrutiny A Bigger Risk To Pharma Than Drug Price Reform, USAIC Panelist Predicts
US antitrust regulators appear poised to take a broader view of disease areas when reviewing mergers, Lazard Freres financial advisory CEO Peter Orszag cautioned.